+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 19Years +
All Genders
ID07563829

Study of NPX372, a Bispecific Antibody Targeting B7-H7 and CD3, for Treatment of Selected Solid Tumors

Led by NextPoint Therapeutics, Inc. · Updated on 2026-09-08

81

Participants Needed

6

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating NPX372, a bispecific antibody drug, in people with certain solid tumor cancers including non-small cell lung cancer, renal cell carcinoma, colorectal carcinoma, pancreatic adenocarcinoma, biliary tract tumors, ovarian carcinoma, and gastric or gastro-esophageal carcinoma. This Phase 1 study aims to assess the safety of NPX372, which targets the B7-H7 protein on cancer cells and activates T cells through CD3 to kill these cancer cells. The study also seeks to find safe and tolerable doses for further research. Participants will receive NPX372 through intravenous infusion. The first treatment cycle lasts three weeks with dosing on day 1 and one week later the first dose is a lower priming dose, followed by a full dose. After these initial doses, NPX372 is administered every other week for up to six months and then about once a month as long as there is benefit, for up to two years. Doses are given over 60 minutes via an IV infusion. During the study, participants are closely monitored by their healthcare providers for side effects and treatment response. Assessments include tracking dose-limiting toxicities, adverse events, lab tests, vital signs, ECGs, and physical exams over up to 24 months. Researchers will measure treatment effects such as tumor response, disease control, progression-free survival, and overall survival for up to two years or until disease progression or other criteria are met. Pharmacokinetics and immune responses to NPX372 are also monitored. Participants must have measurable disease and adequate organ function to join.

CONDITIONS

Brief Title

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

Research Team

T

Trials nextpointtx

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here